JP Morgan initiated coverage on LAVA Therapeutics with a new price target
$LVTX
Biotechnology: Pharmaceutical Preparations
Health Care
JP Morgan initiated coverage of LAVA Therapeutics with a rating of Overweight and set a new price target of $22.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2024 | $11.00 → $2.00 | Outperform → Market Perform | Leerink Partners |
| 12/11/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 10/25/2022 | $9.00 | Buy | H.C. Wainwright |
| 11/16/2021 | $24.00 → $20.00 | Outperform | SVB Leerink |
| 8/17/2021 | $26.00 → $24.00 | Outperform | SVB Leerink |
3 - LAVA Therapeutics NV (0001840748) (Issuer)
4 - LAVA Therapeutics NV (0001840748) (Issuer)
4 - LAVA Therapeutics NV (0001840748) (Issuer)
Leerink Partners downgraded LAVA Therapeutics from Outperform to Market Perform and set a new price target of $2.00 from $11.00 previously
JMP Securities downgraded LAVA Therapeutics from Mkt Outperform to Mkt Perform
H.C. Wainwright initiated coverage of LAVA Therapeutics with a rating of Buy and set a new price target of $9.00
DEFA14A - LAVA Therapeutics NV (0001840748) (Filer)
SC 14D9 - LAVA Therapeutics NV (0001840748) (Subject)
SC TO-T - LAVA Therapeutics NV (0001840748) (Subject)
Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA's two partnered assets and unpartnered programsConsummation of acquisition expected to occur in the fourth quarter of 2025, subject to customary closing conditions and an extraordinary general meeting of shareholdersAnnounced decision to discontinue development of LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome; wind-down of the program has been initiated UTRECHT, The Netherlands, and PHILADELPHIA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " or the "Company")), a clin
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) announced today they have entered a definitive share purchase agreement (the "Purchase Agreement" and the transactions set forth in the Purchase Agreement, the "Transactions") whereby XOMA Royalty will acquire LAVA for (i) between $1.16 and $1.24 per share in cash, consisting of (A) USD $1.16 (the "Base Price Per Share") in cash per share (the "LAVA common stock"), plus (B) an additional amount of cash of up to $0.08 per Share (such amount as finally determined in accordance with the Pur
Focused on evaluation of strategic alternatives, with restructuring and closure of the Netherlands operationsEnrollment in LAVA-1266 Phase 1 continues to progressCash, cash equivalents and short-term investments of $66.6 million as of March 31, 2025 expected to fund operations into 2027 UTRECHT, The Netherlands and PHILADELPHIA, May 14, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company")), a clinical-stage immuno-oncology company focused on its proprietary Gammabody® bispecific gamma delta T cell engagers, today announced recent corporate highlights and financial results for the first quarter ended March 31, 2025. "LAVA's top priority remains deliverin
UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced the appointment of Christy J. Oliger to its board of directors effective March 9, 2023. Ms. Oliger brings extensive commercial, portfolio management, and senior leadership experience to the role. Additionally, Stefan Luzi, Ph.D., will step down from his role on the LAVA Board. "As an accomplished leader in the pharmaceutical and biotechnology industry with deep experience in oncology, Ms. Oliger brings over three deca
UTRECT, The Netherlands and PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023. Dr. Morris will replace Benjamin Winograd, MD, PhD. "During a 25-year tenure in the industry, Dr. Morris has demonstrated a proven track record of advancing novel oncology product candidates from clinical development through global regulatory approvals," said Stephen Hurly, president and chief executive offi
LAVA-051 updated interim data from ongoing Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 American Society of Hematology (ASH) Annual MeetingPresented LAVA-051 clinical pharmacodynamic data demonstrating consistency with mechanism of action data at the Society for Immunotherapy for Cancer (SITC) 2022 Annual MeetingAnnounced exclusive worldwide license agreement with Seagen to advance LAVA-1223, a preclinical bispecific gamma delta T cell engager for EGFR-expressing solid tumorsCash and investments of $92.7 million as of September 30, 2022, plus$50.0 million received from Seagen in October provide cas
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) announced today they have entered a definitive share purchase agreement (the "Purchase Agreement" and the transactions set forth in the Purchase Agreement, the "Transactions") whereby XOMA Royalty will acquire LAVA for (i) between $1.16 and $1.24 per share in cash, consisting of (A) USD $1.16 (the "Base Price Per Share") in cash per share (the "LAVA common stock"), plus (B) an additional amount of cash of up to $0.08 per Share (such amount as finally determined in accordance with the Pur
UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the presentation of initial dose-escalation data from the Phase 1/2a clinical trial of LAVA-051 in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and virtually June 3-7, 2022. "These dose-escalation data from the first four cohorts of our Phase 1/2a clinical tria
SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)
SC 13G/A - LAVA Therapeutics NV (0001840748) (Subject)
SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)